Tackle LDL-C Targets to Cut CVD Risk
A wealth of evidence from both observational and large randomised controlled clinical trials (RCTs) supports the use of statins in a wide variety of patients with hypercholesterolaemia. The absolute benefit of treatment depends on the individual’s absolute risk of cardiovascular disease (CVD) and the absolute reduction of low-density lipoprotein cholesterol (LDL-C) achieved. Rosuvastatin, compared to atorvastatin, has demonstrated high efficacy for LDL-C lowering, enabling patients with hypercholesterolaemia to achieve their lipid goals.
Modern Medicine – Issue 4 2021
